Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
bitBiome has developed the world’s first single-cell genomics technology tailored to microorganisms. Their proprietary platforms enable the accurate decoding of complete genomes from individual microbial cells—unlocking vast numbers of previously inaccessible genes (“dark matter” genes). The company leverages this data to discover novel enzymes and genetic functions useful in biomanufacturing, environmental sustainability, and potentially healthcare. They have built one of the world’s largest microbial genome databases (>800 million microbe genes), supporting both internal projects and external collaborations with industry partners. Clinical results are not applicable as their focus is on enabling technologies/platforms rather than direct therapeutic products.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on bitBiome.